DBV Technologies reported $1.6M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
DBV Technologies USD 1.6M 955K Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Insmed USD 524.42M 98.93M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026